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A B S T R A C T
Zolvix® is a recently introduced anthelmintic drench containing monepantel as the active ingredient. Monepantel
is a positive allosteric modulator of DEG-3/DES-2 type nicotinic acetylcholine receptors (nAChRs) in several
nematode species. The drug has been reported to produce hypercontraction of Caenorhabditis elegans and
Haemonchus contortus somatic muscle. We investigated the effects of monepantel on nAChRs from Ascaris suum
and Oesophagostomum dentatum heterologously expressed in Xenopus laevis oocytes. Using two-electrode voltage-
clamp electrophysiology, we studied the effects of monepantel on a nicotine preferring homomeric nAChR
subtype from A. suum comprising of ACR-16; a pyrantel/tribendimidine preferring heteromeric subtype from O.
dentatum comprising UNC-29, UNC-38 and UNC-63 subunits; and a levamisole preferring subtype (O. dentatum)
comprising UNC-29, UNC-38, UNC-63 and ACR-8 subunits. For each subtype tested, monepantel applied in
isolation produced no measurable currents thereby ruling out an agonist action. When monepantel was con-
tinuously applied, it reduced the amplitude of acetylcholine induced currents in a concentration-dependent
manner. In all three subtypes, monepantel acted as a non-competitive antagonist on the expressed receptors.
ACR-16 from A. suum was particularly sensitive to monepantel inhibition (IC50 values: 1.6 ± 3.1 nM and
0.2 ± 2.3 μM). We also investigated the effects of monepantel on muscle flaps isolated from adult A. suum. The
drug did not significantly increase baseline tension when applied on its own. As with acetylcholine induced
currents in the heterologously expressed receptors, contractions induced by acetylcholine were antagonized by
monepantel. Further investigation revealed that the inhibition was a mixture of competitive and non-competitive
antagonism. Our findings suggest that monepantel is active on multiple nAChR subtypes.
1. Introduction
Soil-Transmitted Helminth (STH) infections in humans and animals
cause significant disease (morbidity & mortality) globally. At least 1.2
billion people suffer from STH infections, with an estimated at-risk
population of 4.5 billion (Bethony et al., 2006; Brooker et al., 2006;
Lammie et al., 2006). Control of these infections is heavily reliant on
the use of anthelmintics as there are no effective vaccines and sanita-
tion is often sub-optimal (Kaminsky et al., 2013). There are a limited
number of drugs used to treat helminth infections (Keiser and Utzinger,
2008). Antinematodal (anthelmintic) drugs can be classified on the
basis of similarity in chemical structure; benzimidazoles, imidazothia-
zoles, tetrahydopyrimidines, macrocyclic lactones, amino-acetonitrile
derivatives, spiroindoles and cyclooctadepsipeptides. The benzimida-
zoles, imidazothiazoles, tetrahydopyrimidines and macrocyclic lactones
are older anthelmintic drug classes. Increasing reports of resistance to
the ‘older’ anthelmintic drugs has encouraged the development of
newer drug classes: amino-acetonitrile derivatives, spiroindoles and
cyclooctadepsipeptides.
Zolvix® (Novartis Animal Health, Greensboro, NC, USA) is a recently
developed anthelmintic for control of gastro-intestinal (GI) nematodes
in sheep. It was first introduced in New Zealand in 2009, and contains
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25mg/ml monepantel (mptl) as the active ingredient (Fig. 1). Mon-
epantel is the first member of the amino-acetonitrile derivative (AAD)
group of anthelmintics. It has a wide range of activity against nema-
todes in sheep, including those resistant to benzimidazoles, imida-
zothiazoles and macrocyclic lactones (Ducray et al., 2008; Kaminsky
et al., 2008a, 2008b). Disappointingly, resistance has developed in in-
fected goats and sheep following treatment with monepantel. The first
field report of monepantel resistance was observed in Teladorsagia cir-
cumcincta and Trichostrongylus colubriformis in goats and sheep on a
farm in the lower North Island in New Zealand<2 years after its initial
use on that farm (Scott et al., 2013). Subsequent cases of resistance to
monepantel have been reported for H. contortus in sheep (Mederos
et al., 2014; Van den Brom et al., 2015). The emergence of field re-
sistance to monepantel within very short periods following treatment
underscores the pressing need to understand the full mode of action of
the drug and thus possible mechanisms of resistance.
Monepantel has a site of action reported to involve ACR-23, a
member of the DEG-3/DES-2 group of nicotinic acetylcholine receptors
(nAChRs) (Lecova et al., 2014). Kaminsky et al. (2008a) showed AADs
to cause hypercontraction of body wall muscles in Caenorhabditis ele-
gans and Haemonchus contortus, leading to spastic paralysis and sub-
sequent death of the worms. These authors further revealed C. elegans
treated with AADs display molting deficits and characteristics of ne-
crosis (Kaminsky et al., 2008a). Subsequent mutagenesis screens in H.
contortus led to the identification of the nAChR subunit gene, mptl-1
(acr-23), as a target for AADs (Rufener et al., 2009). Comparative
genomics of all ligand-gated ion channel (LGIC) genes from different
clades of nematodes reported nematode species lacking the ACR-23/
MPTL-1 nAChR subunits to be insensitive to monepantel. On the con-
trary, nematode species having ACR-23/MPTL-1 were susceptible to
monepantel, thus promoting ACR-23/MPTL-1 nAChR as a principal
target for the AADs (Rufener et al., 2010b). To further elucidate the
mode of action of monepantel, Rufener et al. (2010b) showed that
monepantel on its own did not activate heterologously expressed H.
contortus DEG-3/DES-2 receptors but acted as a type 2 positive allos-
teric modulator when co-applied with choline (Rufener et al., 2010a).
In heterologously expressed C. elegans ACR-23 receptors, monepantel
caused potentiation following activation by betaine (Peden et al.,
2013). Monepantel also acted as a positive allosteric modulator of H.
contortusMPTL-1 and C. elegans ACR-20 receptors at low concentrations
(< 1 nM) but as a direct agonist at high concentrations (> 0.1 μM)
(Baur et al., 2015).
Interestingly, a homolog of C. elegans acr-23 is present in the A. suum
genome (Jex et al., 2011). However, A. suum is not susceptible to
monepantel treatment in vivo (Tritten et al., 2011). Our research seeks
to advance knowledge on the mode of action of monepantel on nAChRs
from Clade III (A. suum) and Clade V (Oesophagostomum dentatum) ne-
matodes. This present study therefore is an investigation of the effects
of monepantel on nAChRs that are widely and ubiquitously expressed in
A. suum (Asu-ACR-16), and those involved in neurotransmission (pyr-
antel/tribendimidine sensitive and levamisole sensitive nAChRs) in O.
dentatum. We find that monepantel also acts selectively as an antagonist
on the nematode nAChRs we studied.
2. Materials and methods
2.1. Xenopus oocyte expression
All nAChR subunit and ancillary factor cRNAs from A. suum (Asu-
acr-16 and Asu-ric-3), O. dentatum (Ode-unc-29, Ode-unc-38, Ode-unc-68
and Ode-acr-8) and H. contortus (Hco-ric-3, Hco-unc-50 and Hco-unc-74)
were prepared as previously described (Abongwa et al., 2016a; Buxton
et al., 2014). Briefly, defolliculated X. laevis oocytes were obtained from
Ecocyte Bioscience (Austin, TX, USA). A Nanoject II microinjector
(Drummond Scientific, Broomall, PA, USA) was used to inject cRNA
into the cytoplasm at the animal pole region of the oocytes. Homomeric
nAChRs comprising Asu-ACR-16 subunits were expressed by co-in-
jecting 25 ng of Asu-acr-16 with 5 ng of Asu-ric-3 in a total volume of
50 nl in nuclease-free water. Heteromeric nAChRs from O. dentatum
were expressed by co-injecting 1.8 ng of each subunit cRNA that make
up the levamisole (Ode-unc-29, Ode-unc-38, Ode-unc-68 and Ode-acr-8)
or pyrantel/tribendimidine (Ode-unc-29, Ode-unc-38 and Ode-unc-63)
receptor with 1.8 ng of each H. contortus ancillary factor (Hco-ric-3, Hco-
unc-50 and Hco-unc-74) in a total volume of 36 nl in nuclease-free
water. Injected oocytes were transferred to 96-well microtiter plates
containing 200 μl incubation solution (100mM NaCl, 2 mM KCl,
1.8 mM CaCl2·2H20, 1mM MgCl2·6H20, 5mM HEPES, 2.5mM Na pyr-
uvate, 100 U·ml−1penicillin and 100 μgml−1 streptomycin, pH 7.5)
and incubated at 19 °C for 5–7 days to allow for functional receptor
expression. Incubation solution was changed daily.
2.2. Two-electrode voltage-clamp electrophysiology
Currents produced by activation of expressed Asu-ACR-16 and Ode
levamisole sensitive and Ode pyrantel/tribendimidine sensitive re-
ceptors were recorded using the two-electrode voltage-clamp electro-
physiology technique as previously described (Abongwa et al., 2016a;
Buxton et al., 2014). 100 μM BAPTA-AM was added to the oocyte in-
cubation solution about 4 h prior to recording to prevent activation of
endogenous calcium-activated chloride currents during recording. Re-
cordings were made using an Axoclamp 2B amplifier (Molecular De-
vices, Sunnyvale, CA, USA) and data acquired on a computer with
Clampex 10.3 (Molecular Devices, Sunnyvale, CA, USA). For all ex-
periments, oocytes were voltage-clamped at −60mV. Microelectrodes
for impaling oocytes were pulled using a Flaming/Brown horizontal
electrode puller (Model P-97; Sutter Instruments, Novato, CA, USA).
The microelectrodes were filled with 3M KCl and their tips carefully
broken with a piece of tissue paper to attain a resistance of 2–5MΩ in
recording solution (100mM NaCl, 2.5 mM KCl, 1 mM CaCl2·2H2O and
5mM HEPES, pH 7.3).
2.3. Muscle contraction assay
Adult A. suum were collected from the IMES slaughterhouse,
Belgrade, Serbia and maintained in Locke's solution (155mM NaCl,
5 mM KCl, 2 mM CaCl2, 1.5 mM NaHCO3 and 5mM glucose) at 32 °C for
5 days. Locke's solution was changed daily. Ascaris muscle flaps for
contraction studies were prepared as described in Trailović et al.
(2015). Briefly, 1 cm muscle body flaps were prepared by dissecting the
anterior 2–3 cm part of the worm. A force transducer in an experimental
bath containing 20ml APF (23mM NaCl, 110mM Na acetate, 24mM
KCl, 6 mM CaCl2, 5 mM MgCl2, 11mM glucose, 5 mM HEPES, pH 7.6)
and 0.1% DMSO and bubbled with nitrogen was attached to each
muscle flap. The bath was maintained at 37 °C during which isometric
contractions of each flap were monitored on a PC computer using a
BioSmart interface and eLAB software (EIUnit, Belgrade). The system
allows real time recording, display and analysis of experimental data.
The preparation was allowed to equilibrate for 15min under an initial
tension of 0.5 g after which acetylcholine (1–100 μM) in the absence
and presence of monepantel (1–30 μM) was applied to the preparation.
Fig. 1. Chemical structure of monepantel [N-[(2S)-2-cyano-1-[5-cyano-2-(tri-
fluoromethyl)phenoxy]propan-2-yl]-4-(trifluoromethylsulfanyl)benzamide].
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2.4. Drugs
Acetylcholine was purchase from Sigma-Aldrich (St Louis, MO,
USA). Zolvix (monepantel 25 mg/ml) was a gift from Dr Michael
Kimber (Iowa State University, Ames, IA). Acetylcholine was dissolved
in either APF or oocyte recording solution. Monepantel was dissolved in
DMSO such that the final DMSO concentration did not exceed 0.1%. All
other chemicals were purchased from Sigma-Aldrich (St Louis, MO,
USA) or Fisher Scientific (Hampton, NH, USA).
2.5. Data analysis
2.5.1. Electrophysiology
Electrophysiology data was measured with Clampfit 10.3
(Molecular devices, Sunnyvale CA, USA) and analyzed with GraphPad
Prism 5.0 (GraphPad Software Inc., La Jolla, CA, USA). All concentra-
tion-response experiments began with a 10 s application of 100 μM
acetylcholine. Increasing concentrations of acetylcholine (0.1–100 μM)
were applied for 10 s at ∼2min intervals. For experiments using
monepantel, an initial 10 s application of 100 μM acetylcholine was
followed after 2min by continuous perfusion of a single concentration
of monepantel (0.3 nM - 30 μM); for the rest of the experiment 10 s
applications of acetylcholine (0.3–100 μM) were used at ∼2min in-
tervals in the presence of monepantel. Responses to each acetylcholine
concentration were normalized to the initial control 100 μM acet-
ylcholine responses and expressed as mean ± s.e.m. Concentration-
response relationships (for each oocyte) were analyzed by fitting log
concentration-response data points with the Hill equation as previously
described (Boulin et al., 2008). % inhibition for monepantel was cal-
culated using 100-Rmax for each experiment and plotted as mean ±
s.e.m. on the concentration-inhibition plots. IC50's were calculated as
previously described (Zheng et al., 2016). We used one-way ANOVA to
test for statistical differences among treatment groups. If the group
means were statistically different (p < .05), we used the Tukey mul-
tiple comparison test to determine significant differences between
groups.
2.5.2. Muscle contraction
Isometric contractions of each Ascaris muscle flap in the absence
and presence of monepantel were monitored on a PC computer using
eLAB software (EIUnit, Belgrade). GraphPad Prism 5.0 (GraphPad
Software Inc., La Jolla, CA, USA) was used to analyze the data.
Responses to each acetylcholine concentration in the absence and
presence of monepantel were expressed as mean ± s.e.m. Single con-
centration-response relationships were fitted to the data as described in
Section 2.5.1.
3. Results
3.1. Effects of monepantel on Asu-ACR-16
Asu-ACR-16 is a homomeric nAChR comprising of Asu-ACR-16
subunits (Abongwa et al., 2016a). This receptor subtype requires only
the ancillary factor Asu-RIC-3 for functional expression in Xenopus oo-
cytes. ACR-16 is nicotine sensitive, but levamisole insensitive, and is
commonly referred to as the nicotine subtype nAChR (Abongwa et al.,
2016a; Ballivet et al., 1996; Raymond et al., 2000; Sattelle et al., 2009).
We tested the effects of different monepantel concentrations (0.3 nM -
1 μM) on Asu-ACR-16 responses to acetylcholine. For control experi-
ments, each acetylcholine concentration from 0.3 to 100 μM was ap-
plied for 10s, Fig. 2A. To test the effects of monepantel, 100 μM acet-
ylcholine was first applied for 10s as control, followed by a 2min wash,
then perfusion with monepantel, after which acetylcholine applications
were repeated in the presence of monepantel, Fig. 2B. For both control
and test experiments, a 2min wash period was applied between drug
applications. Monepantel applied on its own did not cause activation of
Asu-ACR-16, eliminating agonist actions on this receptor subtype. When
co-applied with acetylcholine, monepantel caused a concentration-de-
pendent inhibition of Asu-ACR-16 responses to acetylcholine. Fig. 2C
shows concentration-response plots for these experiments. Monepantel
did not change the EC50 but did significantly reduce Rmax, Fig. 2C and
D, implying non-competitive antagonism. EC50 and Rmax values for
these observations are shown in Table 1.
Fig. 2. Inhibitory effects of monepantel on Asu-ACR-16 (nicotine sensitive receptors). (A)
Sample traces for two-electrode voltage-clamp recording for oocyte responses to acet-
ylcholine for oocytes expressing Asu-ACR-16 subtype nAChR. (B) Sample traces for two-
electrode voltage-clamp recording for oocyte responses to acetylcholine in the presence of
1 μM monepantel. (C) Concentration-response plots for acetylcholine in the absence and
presence of monepantel. Control acetylcholine (n= 4, black); in the presence of 0.3 nM
monepantel (n= 4, light blue); 3 nM monepantel (n= 4, light purple); 30 nM mon-
epantel (n= 4, orange), 0.1 μM monepantel (n=5, olive green), 0.3 μM monepantel
(n= 4, purple), 0.5 μM monepantel (n= 4, pink) and 1 μM monepantel (n=4, green).
(D) Bar chart showing mean ± s.e.m. (n= 4–5) for Rmax for acetylcholine and mon-
epantel. (For interpretation of the references to colour in this figure legend, the reader is
referred to the Web version of this article.)
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3.2. Effects of monepantel on expressed Ode pyrantel/tribendimidine
receptors
Ode pyrantel/tribendimidine receptors were described by Buxton
et al. (2014) to comprise of the nAChR subunits Ode-UNC-29, Ode-UNC-
38 and Ode-UNC-63. Ode pyrantel/tribendimidine receptors require all
3 ancillary factors Hco-RIC-3, Hco-UNC-50 and Hco-UNC-74 from H.
contortus for functional expression in oocytes. To investigate the effects
of monepantel on expressed Ode pyrantel/tribendimidine receptors, we
used the same experimental protocol described for Asu-ACR-16 re-
ceptors in Section 3.1. Fig. 3C shows concentration-response plots for
these experiments. Monepantel alone did not activate Ode pyrantel/
tribendimidine receptors ruling out an agonist action. When co-applied
with acetylcholine, features of non-competitive antagonism (no change
in EC50, reduction in Rmax) were seen for Ode pyrantel/tribendimidine
receptors, Fig. 3C and D. Table 2 shows EC50 and Rmax values for these
experiments.
3.3. Effects of monepantel on expressed Ode levamisole receptors
Previous studies showed the nAChR subunits Ode-UNC-29, Ode-
UNC-38, Ode-UNC-63 and Ode-ACR-8 are required to express the Ode
levamisole sensitive receptors in Xenopus oocytes (Buxton et al., 2014).
This was in accordance with previous work by Boulin et al. (2011) who
expressed functional levamisole receptors in Xenopus oocytes when
these oocytes were injected with Hco-UNC-29, Hco-UNC-38, Hco-UNC-
63 and Hco-ACR-8 from H. contortus. The levamisole receptors required
all 3 ancillary factors Hco-RIC-3, Hco-UNC-50 and Hco-UNC-74 from H.
contortus for its functional expression in oocytes (Boulin et al., 2008,
2011; Buxton et al., 2014). To investigate the effects of monepantel on
expressed Ode levamisole receptors, we used the same experimental
protocol described for Asu-ACR-16 receptors in Section 3.1. The mon-
epantel concentrations tested on levamisole receptors were from 1 to
30 μM. Sample traces and concentration-response plots for these ex-
periments are shown in Fig. 4A, B, & C. Again, monepantel applied
alone failed to activate the Ode levamisole receptors, demonstrating no
agonist action. As expected for a non-competitive antagonist, mon-
epantel did not produce any significant change in EC50 but did cause a
significant reduction in Rmax as shown in Fig. 4C and D. EC50 and Rmax
values for these experiments are reported in Table 3.
3.4. Effects of monepantel on Ascaris body muscle flaps
The results we obtained for expressed nicotine (Asu-ACR-16), Ode
pyrantel/tribendimidine (Ode-UNC-29:Ode-UNC-38:Ode-UNC-63) and
Ode levamisole (Ode-UNC-29:Ode-UNC-38:Ode-UNC-63:Ode-ACR-8)
subtype nAChRs which we describe in Sections 3.1, 3.2 and 3.3, en-
couraged us to investigate the in vivo effects of monepantel on Ascaris
muscle. Fig. 5A shows representative traces of the effects of adding
increasing concentrations of acetylcholine in the absence and presence
of monepantel on isometric contractions of an Ascaris body flap pre-
paration. Application of increasing concentrations of acetylcholine from
1 to 100 μM produced concentration-dependent contraction responses
Table 1
Effect of monepantel on acetylcholine EC50 and Rmax values for Asu-ACR-16.
EC50 (mean ± s.e.m., n) Rmax (mean ± s.e.m., n)
Acetylcholine 5.9 ± 0.3 μM, n=4 97.5 ± 1.2%, n= 4
+0.3 nM monepantel 7.3 ± 0.0 μM, n=4 91.4 ± 6.6%, n= 4
+3 nM monepantel 7.1 ± 0.1 μM, n=4 75.3 ± 5.1%, n= 4
+30 nM monepantel 6.8 ± 0.8 μM, n=4 63.6 ± 4.2%, n= 4
+0.1 μM monepantel 9.2 ± 1.0 μM, n=5 61.6 ± 5.8%, n= 5
+0.3 μM monepantel 6.9 ± 0.2 μM, n=4 38.2 ± 0.8%, n= 4
+0.5 μM monepantel 7.0 ± 0.5 μM, n=4 32.5 ± 3.2%, n= 4
+1 μM monepantel 9.1 ± 1.3 μM, n=4 19.9 ± 0.5%, n= 4
Fig. 3. Inhibitory effects of monepantel on Ode pyrantel/tribendimidine preferring
nAChRs. (A) Sample traces for two-electrode voltage-clamp recording for oocyte re-
sponses to acetylcholine for oocytes expressing Ode pyrantel/tribendimidine subtype
nAChR. (B) Sample traces for two-electrode voltage-clamp recording for oocyte responses
to acetylcholine in the presence of 0.3 μM monepantel. (C) Concentration-response plots
for acetylcholine in the absence and presence of monepantel. Control acetylcholine
(n= 4, black); in the presence of 0.3 μM monepantel (n= 5, purple); 1 μM monepantel
(n= 4, green); 3 μM monepantel (n= 4, red) and 10 μM monepantel (n=4, blue). (D)
Bar chart showing mean ± s.e.m. (n=4–5) for Rmax for acetylcholine and monepantel.
(For interpretation of the references to colour in this figure legend, the reader is referred
to the Web version of this article.)
Table 2
Effect of monepantel on acetylcholine EC50 and Rmax values for Ode pyrantel/tribendi-
midine receptors.
EC50 (mean ± s.e.m., n) Rmax (mean ± s.e.m., n)
Acetylcholine 11.3 ± 1.3 μM, n=4 118.2 ± 4.5%, n= 4
+0.3 μM monepantel 13.2 ± 1.4 μM, n=5 69.4 ± 3.5%, n= 5
+1 μM monepantel 10.4 ± 1.0 μM, n=4 56.8 ± 4.8%, n= 4
+3 μM monepantel 12.9 ± 1.5 μM, n=4 29.0 ± 0.9%, n= 4
+10 μM monepantel 14.5 ± 1.6 μM, n=4 13.4 ± 0.6%, n= 4
M. Abongwa et al. IJP: Drugs and Drug Resistance 8 (2018) 36–42
39
which were inhibited by monepantel in a concentration-dependent
manner. Monepantel on its own did not produce any significant change
in baseline tension. Washing reversed the inhibition caused by mon-
epantel to near control levels. Concentration-response plots (mean ±
s.e.m.) for acetylcholine and monepantel are shown in Fig. 5B. 1 μM
monepantel produced a significant reduction in the maximum response,
Rmax and also shifted the EC50 to the right. Increasing the concentration
of monepantel to 3, 10 and 30 μM further reduced the Rmax and caused
a further right-shift in the EC50, characteristic of a mixture of compe-
titive and non-competitive antagonism. The activity of monepantel on
Ascaris muscle flaps was rather interesting, as previous authors have
showed monepantel (600mg/kg) to lack in vivo activity against A. suum
(Tritten et al., 2011). Table 4 shows EC50 and Rmax values for acet-
ylcholine alone and in the presence of 1–30 μM monepantel.
In an effort to infer what nAChR subtypes monepantel maybe acting
on, we generated inhibition plots for Asu-ACR-16, Ode pyrantel/tri-
bendimidine and Ode levamisole subtype nAChRs, Fig. 5C and Table 5.
The inhibition caused by monepantel (Fig. 5C) on Asu-ACR-16 had 2
components, one with an IC50 of 1.6 ± 3.1 nM, and the other with an
IC50 of 0.2 ± 2.3 μM, suggesting the likelihood of more than one
Fig. 4. Monepantel inhibits Ode levamisole preferring receptors. (A) Sample traces for
two-electrode voltage-clamp recording for oocyte responses to acetylcholine for oocytes
expressing Ode levamisole subtype nAChR. (B) Sample traces for two-electrode voltage-
clamp recording for oocyte responses to acetylcholine in the presence of 3 μM mon-
epantel. (C) Concentration-response plots for acetylcholine in the absence and presence of
monepantel. Control acetylcholine (n= 4, black); in the presence of 1 μM monepantel
(n=4, green); 3 μMmonepantel (n= 4, red); 10 μMmonepantel (n= 4, blue) and 30 μM
monepantel (n=5, grey). (D) Bar chart showing mean ± s.e.m. (n= 4–5) for Rmax for
acetylcholine and monepantel. (For interpretation of the references to colour in this figure
legend, the reader is referred to the Web version of this article.)
Table 3
Effect of monepantel on acetylcholine EC50 and Rmax values for Ode levamisole receptors.
EC50 (mean ± s.e.m., n) Rmax (mean ± s.e.m., n)
Acetylcholine 2.7 ± 0.4 μM, n=4 108.8 ± 1.0%, n=4
+1 μM monepantel 3.8 ± 0.4 μM, n=4 87.9 ± 1.2%, n= 4
+3 μM monepantel 2.7 ± 0.4 μM, n=4 69.3 ± 3.2%, n= 4
+10 μM monepantel 2.2 ± 0.4 μM, n=4 25.0 ± 1.4%, n= 4
+30 μM monepantel 1.8 ± 0.3 μM, n=5 3.9 ± 0.1%, n= 5
Fig. 5. Inhibition of Ascaris suum muscle flap contractions by monepantel. (A) Isometric
contractions of A. suum muscle flap following application of increasing acetylcholine
concentrations and antagonism by 10 μM (blue bar) and 30 μM (grey bar) monepantel. (B)
Concentration-contraction response plots for acetylcholine showing mean ± s.e.m. bars.
Control acetylcholine (n= 11, black); in the presence of 1 μMmonepantel (n= 6, green),
3 μM monepantel (n= 6, red), 10 μM monepantel (n= 5, blue) and 30 μM monepantel
(n= 5, grey). (C) Inhibition curve plotted as mean ± s.e.m. (n= 4–5) maximum re-
sponse versus concentration of monepantel and Hill equation fit with an IC50 of
1.6 ± 3.1 nM and 0.2 ± 2.3 μM for Asu-ACR-16, 1.7 ± 0.7 μM for Ode pyrantel/tri-
bendimidine, and 5.0 ± 0.5 μM for Ode levamisole receptors. (For interpretation of the
references to colour in this figure legend, the reader is referred to the Web version of this
article.)
Table 4
Effect of monepantel on acetylcholine EC50 and Rmax values for A. suum muscle flaps
(n= 5–11 for each data point fitted).
EC50 (log EC50 ± s.e.m.) Rmax (mean ± s.e.m.)
Acetylcholine 5.3 μM (0.7 ± 0.5) 1.7 ± 0.4 g
+1 μM monepantel 12.5 μM (1.1 ± 0.6) 1.8 ± 1.3 g
+3 μM monepantel 16.0 μM (1.2 ± 0.3) 1.1 ± 0.3 g
+10 μM monepantel 18.4 μM (1.3 ± 0.4) 1.1 ± 0.5 g
+30 μM monepantel 23.5 μM (1.4 ± 0.7) 0.5 ± 0.4 g
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binding site for monepantel on Asu-ACR-16. The IC50 monepantel for
Ode pyrantel/tribendimidine receptors (1.7 ± 0.7 μM) was seen to be
lower than that for the Ode levamisole receptors (5.0 ± 0.5 μM). The
Ode pyrantel/tribendimidine receptors appear to be more sensitive to
monepantel than the Ode levamisole receptors. When we compare these
results with that of the in vivo effects shown in Fig. 5B, monepantel
appears to be acting on a mixture of the Asu-ACR-16, Ode pyrantel/
tribendimidine and Ode levamisole nAChRs.
4. Discussion
4.1. Non-competitive antagonism of monepantel on expressed A. suum and
O. dentatum receptors
In contrast to the positive allosteric modulatory effects of mon-
epantel on DEG-3/DES-2 nAChRs, we found monepantel to produce
non-competitive inhibition of Asu-ACR-16 and Ode levamisole sensitive
and Ode pyrantel/tribendimidine sensitive nAChRs. These observations
were consistent with results obtained from our muscle contraction
assay. In all cases, monepantel produced no change in EC50 but a sig-
nificant reduction in Rmax, an observation which was seen to be con-
centration-dependent. Of all three receptor subtypes expressed in
Xenopus oocytes, Asu-ACR-16 was most sensitive to monepantel as re-
flected by its IC50 values of 1.6 ± 3.1 nM and 0.2 ± 2.3 μM. This was
followed by the Ode pyrantel/tribendimidine receptor with an of IC50 of
1.7 ± 0.7 μM, and the Ode levamisole receptor with an IC50 of
5.0 ± 0.5 μM. Monepantel had a potent inhibitory effect on Asu-ACR-
16, involving 2 components: one in which the maximum inhibition was
only 40%, giving an IC50 value of 1.6 ± 3.1 nM and the other in which
the maximum inhibition nearly reached 100%, giving an IC50 value of
0.2 ± 2.3 μM. These observations suggest that monepantel also acts
via negative allosteric modulation, involving more than one binding
site as is the case with abamectin and other negative allosteric mod-
ulators of nAChRs (Abongwa et al., 2016b; Zheng et al., 2016).
4.2. Mixed antagonism of monepantel on A. suum muscle flap
Monepantel causes hypercontraction of both C. elegans and H. con-
tortus (Kaminsky et al., 2008a). In our electrophysiology experiments,
monepantel produced an inhibitory effect on inward currents induced
by acetylcholine. To further characterize the inhibition by monepantel,
we tested different concentrations of monepantel in the presence of
acetylcholine on A. suum muscle flaps. With all concentrations tested,
monepantel produced a significant concentration-dependent reduction
in Rmax, and a right-shift in EC50. In sharp contrast to the effects on C.
elegans and H. contortus this indicates monepantel is a mixed antagonist
of Ascaris muscle contraction. These results are likely due to the mixed
nAChR populations on nematode muscle (Robertson et al., 1999, 2002;
Qian et al., 2006). Asu-ACR-16 is extremely sensitive to monepantel;
the observed shift in EC50 in the muscle flap experiment is likely due to
the almost complete inhibition of Asu-ACR-16 at the concentrations
tested in the muscle. The non-competitive aspect of the inhibition is in
agreement with the results obtained from the Ode levamisole sensitive
and Ode pyrantel/tribendimidine sensitive receptors.
4.3. Conclusion
Our results indicate that monepantel acts as an antagonist of Ascaris
muscle contraction, and as a non-competitive antagonist, with subtype
selective effects, of expressed nAChR subtypes from A. suum (Clade III)
and O. dentatum (Clade V). Non-competitive antagonism of monepantel
on expressed nAChRs which we show in our research adds to the re-
ported mode of action of monepantel as a positive allosteric modulator
of expressed receptors of the DEG-3/DES-2 group of nAChRs. Thus, il-
lustrating the complexity of the mode of action of the drug; involving
more than one target site. Detailed understanding of the mode of action
of antinematodal drugs is necessary, especially when considered for use
in combination therapy/products, an approach proven to be highly
effective for parasite control. As with many pharmacological agents we
find that the mode of action of monepantel is complex and the drug is
active on multiple nAChR subtypes.
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